Type 1 diabetes is caused by an
autoimmune destruction of the insulin-producing pancreatic beta cells.
This results in high blood glucose levels, and it is therefore vital
that people living with type 1 diabetes receive daily insulin
treatment. Based on almost 100 years of experience in discovering and
producing treatments for people with diabetes, Novo Nordisk scientists
are advancing research to reduce the number of insulin injections
required to maintain good glycaemic control, and to prevent low blood
glucose (hypoglycaemic) episodes. We are also progressing our research
in regenerative medicine such as stem cell therapy, which may one day
be used as a curative treatment of type 1 diabetes.
DISEASE EXPERIENCE EXPERT PANELS
At Novo Nordisk, we consider people living with serious chronic diseases to be experts. That's why we invite them to become members of our Disease Experience Expert Panels (DEEPs). DEEP members are able to provide disease-specific insights and advice based on real-world experiences. This input guides us as we work to develop better treatments and meaningful support for people living with chronic diseases worldwide.
After 20 years working in diabetes research, Jacob Sten
Petersen, Corporate Vice President and Head of Stem Cell R&D at
Novo Nordisk, learned that his daughter Vita has type 1 diabetes. Here
he reflects on his very personal motivation to find a cure for the
disease, and on the progress of Novo Nordisk’s stem cell
Watch Jacob’s story
Hypoglycaemia occurs when the level of glucose in the blood becomes too low. Symptoms include, but are not limited to, sweating, increased heart rate, hunger, dizziness, impaired vision, and even loss of consciousness in severe cases. People with type 1 diabetes are dependent on insulin treatment for survival, but this carries an inherent risk of hypoglycaemia. The psychological burden of patients' anxiety, together with the serious long-term consequences of hypoglycaemia, which include cognitive decline, cardiovascular events and even death, mean that there is a significant need for innovative treatments that offer low or no risk of hypoglycaemia.
Erica Nishimura, Scientific Vice President of Diabetes
Research, talks about our common goal of designing an insulin that
could one day eliminate hypoglycaemic episodes.
Novo Nordisk takes part in a new European collaborative research project Hypo-RESOLVE - an international consortium of experts from academia, industry and civil society. The project aims to provide evidence-based insights into all aspects of hypoglycaemia to better understand its impact on people living with diabetes.
Explore our scientists’ work on new type 1 diabetes treatments.
To contribute to the
scientific community in our areas of expertise, we take pride in
publishing our scientists’ new findings. Visit our library to review
some of their recent work.